Vector Science & Therapeutics develops novel biomechanical devices and active localized drug delivery platforms to equip clinicians with site-directed interventions where precision matters and systemic risk are unacceptable.
Three pillars. One platform. From adaptive intelligence to site-directed delivery to continuous therapeutic presence - without systemic side effects.
Intelligent, data-informed formulations and devices that respond to tissue conditions - delivering exactly what the body needs, when it needs it.
Precisely directed therapies using active transdermal platforms that guide therapeutic compounds to exactly the right anatomical target site.
Long-lasting therapeutic effects that support true musculoskeletal tissue regeneration - moving beyond symptom masking to genuine, durable healing.
One throughline. Right therapy, right place, right duration.
Vector Science & Therapeutics Corp. (TSXV: PAIN) has entered into a three-year development and manufacturing agreement with MPP Group LLC, a key milestone advancing the Company’s therapeutic delivery platform toward commercial-scale production.
Vector Science & Therapeutics Corp. (TSXV: PAIN) announces the filing of a provisional patent application covering a novel microneedle catheter platform designed to enable precise, minimally invasive intratumoral drug delivery, advancing the Company’s site-directed therapeutic intervention portfolio.
Vector Science and Therapeutics Corp. (TSXV: PAIN) announces the appointment of Tommy Thompson — former U.S. Secretary of Health and Human Services and four-term Governor of Wisconsin — as Chairman of the Board of Directors.
We welcome conversations with investors, clinical partners, and healthcare organizations aligned with our mission.